Adults usually have to show a diagnosis of cardiovascular disease, have a BMI of 27 or greater, demonstrate participation in an active lifestyle program, and have no history of type 2 diabetes
In terms of regulation and reimbursement, international health authorities are beginning to approve GLP1s for obesity, which could materially broaden eligibility
Watch your diet: You can eat normally, but try to avoid dairy, alcohol, and spicy food until your stomach settles
Other side effects to monitor Patients switching between formulations should also be aware of potential headaches associated with GLP-1 therapy , tirzepatide body aches , muscle pain , insomnia , and semaglutide-related sleep disruption